Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.24 USD
Change Today -0.62 / -5.71%
Volume 1.9M
ZIOP On Other Exchanges
As of 8:10 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

ziopharm oncology inc (ZIOP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $14.40
52 Week Low
10/14/14 - $2.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZIOPHARM ONCOLOGY INC (ZIOP)

ziopharm oncology inc (ZIOP) Related Bloomberg News

View More Bloomberg News

ziopharm oncology inc (ZIOP) Related Businessweek News

No Related Businessweek News Found

ziopharm oncology inc (ZIOP) Details

ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in collaboration with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability. The company is also developing programs in various stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System(r) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. Its pipeline includes various gene and cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The company has collaboration with Intrexon Corporation. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

27 Employees
Last Reported Date: 02/26/15

ziopharm oncology inc (ZIOP) Top Compensated Officers

Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $238.7K
Chief Operating Officer, Chief Legal Officer,...
Total Annual Compensation: $472.5K
Compensation as of Fiscal Year 2014.

ziopharm oncology inc (ZIOP) Key Developments

Intrexon and ZIOPHARM to Develop Immunotherapies for Treatment of Graft-Versus-Host Disease

Intrexon Corporation announced it has formed a new Exclusive Channel Collaboration (ECC) with ZIOPHARM Oncology, Inc. for the treatment and prevention of graft-versus-host disease (GvHD), a major complication of allogeneic hematopoietic stem-cell transplantation (HSCT) which significantly impairs the quality of life and survival of many recipients. The collaboration will focus on addressing the underlying pathologies of GvHD through engineered cell platforms to express and deliver interleukin-2 (IL-2), a cytokine critical for modulation of the immune system. Through the ECC, the companies plan to pursue engineered cell therapy strategies, used either separately or in combination, for targeted treatment of GvHD. The first approach is infusion of regulatory T cells (Tregs) conditionally expressing IL-2 utilizing Intrexon's proprietary gene control approaches such as its RheoSwitch platform. The second is deployment of orally-delivered microbe-based ActoBiotics therapeutics expressing IL-2 to modulate immune function. Allogeneic HSCT is used for the treatment of various diseases including hematological malignancies, immunological deficiencies as well as non-malignant conditions. Approximately 40 to 60% of HSCT recipients develop GvHD, either acute or chronic, when immune (graft) cells in a transplant patient recognize their engrafted host as foreign and attack the patient's (host) cells. Immunosuppressive agents and systemic steroids routinely used to treat GvHD have limited efficacy and toxicity, defining the need for safer, more effective therapies. Human studies have shown that administration of low-dose subcutaneous IL-2 in patients with steroid-refractory GvHD acts via Tregs to ameliorate its manifestations. The ECC intends to expand on the benefits of IL-2 immunotherapy under Intrexon's technologies to generate clinical-grade Tregs that can precisely deliver IL-2. In addition, the ActoBiotics platform will be harnessed for its ability to target delivery of IL-2 to the digestive tract, a site which plays a significant role in the body's immune system. These new ways of treating and preventing GvHD have the potential to broaden the number of patients eligible to receive allogeneic HSCT and also increase the number of effective donor/recipient combinations. Under the terms of the agreement, Intrexon will receive a technology access fee of $10 million in cash and reimbursement for all research and development costs. The agreement also provides for equal sharing of operating profits.

Intrexon Corporation, ZIOPHARM Oncology, Inc. - Special Call

To discuss their GvHD exclusive channel collaboration

ZIOPHARM Oncology, Inc. Appoints Scott Tarriff to its Board of Directors

ZIOPHARM Oncology, Inc. announced the appointment of Scott Tarriff to the company's Board of Directors. Mr. Tarriff, who serves as President, Chief Executive Officer and a Director of Eagle Pharmaceuticals, brings more than 25 years of pharmaceutical industry experience to ZIOPHARM. Prior to joining Eagle, Mr. Tarriff held various executive positions at Par Pharmaceutical Companies, Inc. including serving as President and Chief Executive Officer from September 2003 to September 2006, after joining Par in 1998.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZIOP:US $10.24 USD -0.62

ZIOP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aduro Biotech Inc $21.71 USD -0.10
Advaxis Inc $9.81 USD -0.54
Dynavax Technologies Corp $22.51 USD -1.44
Exact Sciences Corp $7.63 USD -0.61
Genocea Biosciences Inc $7.76 USD +0.96
View Industry Companies

Industry Analysis


Industry Average

Valuation ZIOP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 924.4x
Price/Book 12.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 863.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIOPHARM ONCOLOGY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at